Patents by Inventor Michel Sadelain

Michel Sadelain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN RECOGNIZING RECEPTORS TARGETING UPAR AND USES THEREOF
    Publication number: 20240131070
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 25, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
    Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Paul Balderes, Ivo C. Lorenz, Zeda Zhang
  • ANTIGEN RECOGNIZING RECEPTORS TARGETING UPAR AND USES THEREOF
    Publication number: 20240123069
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 18, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Zeda Zhang
  • ANTI-UPAR ANTIBODIES AND USES THEREOF
    Publication number: 20240117066
    Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to uPAR and methods of using such antibodies or antigen-binding fragments thereof same.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 11, 2024
    Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute For Cancer Research, Memorial Hospital For Cancer and Allied Diseases
    Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20240091353
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: June 13, 2023
    Publication date: March 21, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher C. Kloss, Michel Sadelain
  • Enhanced chimeric antigen receptors and uses thereof
    Patent number: 11932690
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: March 19, 2024
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Judith Feucht, Mohamad Hamieh, Jie Sun, Jorge A. Mansilla-Soto
  • GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES
    Publication number: 20240066148
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: January 26, 2023
    Publication date: February 29, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY
    Publication number: 20230381315
    Abstract: The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule); and a gene disruption of a CD70 locus. The gene disruption of the CD70 locus can improve the activity and/or efficiency of the cells.
    Type: Application
    Filed: April 25, 2023
    Publication date: November 30, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Jorge Mansilla-Soto, Sacha P. Haubner
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF
    Publication number: 20230346938
    Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.
    Type: Application
    Filed: October 24, 2022
    Publication date: November 2, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORAIL HOSPITAL FOR CANCER AND ALLIED DISEASES, MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Judith FEUCHT, Jorge MANSILLA-SOTO, Isabelle RIVIERE, Michel SADELAIN, Loic VINCENT, Gary SHAPIRO, Mei Rosa NG, Dan TAVARES, Xingyue HE
  • USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20230312706
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: May 16, 2023
    Publication date: October 5, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department of Health and Human Services
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • Globin gene therapy for treating hemoglobinopathies
    Patent number: 11753654
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: September 12, 2023
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Annalisa Cabriolu
  • Globin gene therapy for treating hemoglobinopathies
    Patent number: 11717579
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: August 8, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Compositions and methods for immunotherapy
    Patent number: 11712469
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: August 1, 2023
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher C. Kloss, Michel Sadelain
  • Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors
    Patent number: 11702472
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: July 18, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY
    Publication number: 20220401475
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward tumor and pathogen antigens. It relates to immunoresponsive cells comprising two or more chimeric antigen receptors (CARs), wherein the CARs comprise different intracellular signaling domains, in particular, the intracellular signaling domains of the CARs comprise different co-stimulatory molecules.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 22, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Mohamad Hamieh, Judith Feucht
  • CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF
    Publication number: 20220363775
    Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MILLENNIUM PHARMACEUTICALS, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Sascha P. Haubner, Jorge Mansilla-Soto, Xingyue He, Gary Shapiro
  • METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS
    Publication number: 20220275363
    Abstract: The present disclosure provides methods for identifying genomic safe harbors in a genome (e.g., a human genome).
    Type: Application
    Filed: March 17, 2022
    Publication date: September 1, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Ashlesha Odak
  • GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION
    Publication number: 20220211761
    Abstract: The present disclosure provides genomic safe harbors (GSHs) at which transgenes can be integrated for stable and reliable expression, without disrupting the expression or regulation of the endogenous genes. The present disclosure further provides genetically modified cells comprising a transgene that is integrated within the GSHs disclosed herein. The present disclosure further provides compositions, kits, and formulations comprising genetically modified cells disclosed herein.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 7, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Ashlesha Odak
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20220162340
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 26, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Victor D. Fedorov, Michel Sadelain
  • FUSION POLYPEPTIDE FOR IMMUNOTHERAPY
    Publication number: 20220133802
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing immune responses toward tumor and pathogen antigens. It relates to fusion polypeptide that can be expressed in cells (e.g., immunoresponsive cells comprising an antigen-recognizing receptor) to improve the activity and/or efficiency of the cells. In certain embodiments, the fusion polypeptide comprises an extracellular domain and a transmembrane domain of a co-stimulatory ligand, and an intracellular domain of a co-stimulatory molecule.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 5, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Mohamad Hamieh, Anton Dobrin
  • MESOTHELIN CARS AND USES THEREOF
    Publication number: 20220125905
    Abstract: The presently disclosed subject matter provides polypeptide compositions comprising a chimeric antigen receptor (CAR) that targets mesothelin; and a dominant negative form of programmed death 1 (PD-1 DN). Also provided are immunoresponsive cells comprising such polypeptide compositions and uses of the polypeptide compositions and immunoresponsive cells for treatment, e.g., for treating solid tumors.
    Type: Application
    Filed: November 15, 2021
    Publication date: April 28, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Prasad S. Adusumilli, Michel Sadelain